Physician profile
Min Clapham
NPI 1881957207
$6,638.51
in general payments reported to CMS, 2019-2025
32 companies · $1,187 in 2025
The $1,187 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.45 · 2021: $387 · 2022: $2,375 · 2023: $2,520 · 2024: $154 · 2025: $1,187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,127 · Consulting Fee: $1,602 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,127.03 |
| Consulting Fee | $1,602.00 |
| Education | $131.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,949.02 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,224.90 | 2021-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $753.59 | 2020-2025 | Tezspire, Breztri, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $390.70 | 2021-2025 | Ofev, Jascayd |
| Gilead Sciences, INC. | $271.79 | 2023-2024 | Veklury |
| Janssen Pharmaceuticals, INC | $247.77 | 2021-2023 | Xarelto |
| Mallinckrodt Hospital Products INC. | $213.15 | 2022-2025 | Acthar |
| Genzyme Corporation | $200.74 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $178.06 | 2022-2025 | Glassia |
| Insmed, INC. | $138.25 | 2021-2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $114.17 | 2021-2025 | Prolastin-C Liquid |
| Philips North America LLC | $105.31 | 2022-2025 | Vest Therapy Und |
| Actelion Pharmaceuticals US, INC. | $101.28 | 2022 | |
| Sanofi-Aventis U.S. LLC | $99.75 | 2025 | |
| Pfizer INC. | $97.10 | 2021-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $94.36 | 2022-2025 | Hillrom - Monarch Airway Clearance System |
| Amgen INC. | $74.35 | 2021-2025 | Tezspire |
| Mylan Specialty L.P. | $56.30 | 2022 | |
| Pulmonx Corporation | $45.47 | 2023-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Electromed, INC. | $38.68 | 2022-2025 | Smartvest |
| Inogen, INC. | $31.29 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $27.44 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $24.53 | 2025 | Vibativ |
| Viatris Specialty LLC | $21.42 | 2025 | Yupelri |
| Verona Pharma, INC. | $20.77 | 2025 | Ohtuvayre |
| Aimmune Therapeutics, INC. | $20.16 | 2025 | Vowst |
| Novartis Pharmaceuticals Corporation | $20.00 | 2025 | |
| Merck Sharp & Dohme LLC | $19.30 | 2022 | |
| Ani Pharmaceuticals, INC. | $16.11 | 2022 | |
| Covis Pharma Gmbh | $15.09 | 2022 | |
| Inspire Medical Systems, INC. | $14.60 | 2025 | Inspire |
| Teva Pharmaceuticals USA, INC. | $13.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Min Clapham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.